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Abstract: Adverse drug reactions (ADRs) are an important health issue. While prevalence and 
risk factors associated with ADRs in the general adult population have been well documented, 
much less is known about ADRs in the elderly population. The aim of this study was to review 
the published literature to estimate the prevalence of ADRs in the elderly in the acute care setting 
and identify factors associated with an increased risk of an ADR in the elderly. A systematic 
review of studies published between 2003 and 2013 was conducted in the Cochrane Database 
of Systematic Reviews, EMBASE, Google Scholar and MEDLINE. Key search terms included: 
“adverse drug reactions”, “adverse effects”, “elderly patients and hospital admission”, “drug 
therapy”, “drug adverse effects”, “drug related”, “aged”, “older patients”, “geriatric”, “hospi-
talization”, and “emergency admissions”. For inclusion in the review, studies had to focus on 
ADRs in the elderly and had to include an explicit definition of what was considered an ADR 
and/or an explicit assessment of causality, and a clear description of the method used for ADR 
identification, and had to describe factors associated with an increased risk of an ADR. Fourteen 
hospital-based observational studies exploring ADRs in the elderly in the acute care setting were 
eligible for inclusion in this review. The mean prevalence of ADRs in the elderly in the studies 
included in this review was 11.0% (95% confidence interval [CI]: 5.1%–16.8%). The median 
prevalence of ADRs leading to hospitalization was 10.0% (95% CI: 7.2%–12.8%), while the 
prevalence of ADRs occurring during hospitalization was 11.5% (95% CI: 0%–27.7%). There 
was wide variation in the overall ADR prevalence, from 5.8% to 46.3%. Female sex, increased 
comorbid complexity, and increased number of medications were all significantly associated 
with an increased risk of an ADR. Retrospective studies and those relying on identification by 
the usual treating team reported lower prevalence rates. From this review, we can conclude that 
ADRs constitute a significant health issue for the elderly in the acute care setting. While there 
was wide variation in the prevalence of ADRs in the elderly, based on the findings of this study, 
at least one in ten elderly patients will experience an ADR leading to or during their hospital 
stay. Older female patients and those with multiple comorbidities and medications appear to 
be at the highest risk of an ADR in the acute care setting.
Keywords: drug utilization, hospital 
Introduction
Pharmacotherapy plays an important role in the maintenance of health. Many conditions 
rely on medication to manage symptoms, slow disease progression, or to prevent the 
development of future illnesses. While medications may provide considerable benefit 
in the maintenance of health, all medications also have a risk of adverse or unwanted 
effects, and evaluating the risk/balance benefit associated with use of a particular 
medication is a critical step in the decision to use pharmacotherapy. Adverse drug 
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reactions (ADRs) are adverse or unintended effects associ-
ated with medication and have been defined by the World 
Health Organization (WHO) as “noxious and unintended 
responses to drugs occurring at doses normally used in man 
for the prophylaxis, diagnosis or therapy of disease, or for 
modification of physiological function”.1 ADRs are an impor-
tant component of adverse drug events, which encompass 
medication-related harm associated with ADRs as well as 
that secondary to errors.2
ADRs have a significant impact on heath, with between 
5% and 7% of all hospitalizations being due to an ADR and 
with a further 10% to 20% of all hospitalized patients expe-
riencing an ADR during their hospital admission.2–4 Between 
3% and 6% of ADRs are fatal or have serious consequences, 
with an estimated 140,000 fatalities secondary to ADRs 
occurring annually in the USA.5–8 The estimated impact on 
hospital costs exceeds $30 billion, or 5% of total hospital 
running costs per annum.8–10 
While the prevalence and impact of ADRs has been 
well studied in the general adult population,11 much less is 
known about ADRs in the elderly. Older persons experience 
an increased disease burden and a corresponding increase in 
medication utilization, which has been well documented.12 
With this increased medication use and health complexity, 
there is a corresponding increased risk of ADRs. As well as 
increases in medication number and comorbid conditions, 
there are a variety of age-related physiological changes 
affecting the pharmacokinetics and pharmacodynamics of 
medications, which may further increase the risk of ADRs 
in older persons.
Despite the potential increased risk of ADRs in older 
persons, little is known about the prevalence of ADRs and 
the associated risk factors in the elderly population. The aim 
of this review was to determine the prevalence of ADRs, 
leading to and during admission, in the elderly, to identify 
characteristics associated with an increased ADR risk in 
elderly persons and to examine how the prevalence varies 
with different study designs and identification strategies in 
the acute care setting. 
Methods
Data sources and study selection 
An electronic search of the Cochrane Database of Systematic 
Reviews, EMBASE, Google Scholar, and MEDLINE for 
studies published between 2003 and 2013 was conducted. 
Medical Subject Headings terminology was used where 
possible (in MEDLINE and Cochrane) and keywords used 
in those databases not using Medical Subject Headings 
terminology (EMBASE and Google scholar). The terms 
used were: “adverse drug reactions”, “adverse effects”, and 
“elderly patients” and “hospital admission”. Additional 
search terms used included: “drug therapy”, “drug adverse 
effects”, “drug related”, “aged”, “older patients”, “geriatric”, 
“hospitalization”, and “emergency admissions”. 
All titles and abstracts of identified studies were examined 
for potential relevance. Reference lists of identified studies 
were reviewed to locate other relevant original studies. Eligible 
study titles and abstracts were screened for relevance, and 
a manual cross-reference search of the relevant papers was 
performed to identify additional articles. Two independent 
reviewers assessed each study, and final consensus was reached 
regarding inclusion of each study before data extraction.
Inclusion criteria
Studies were included in the review if they were published in 
English with a primary aim to assess ADR prevalence, either 
leading to hospitalization or during admission, in the elderly 
(65 years) in an acute care setting, using observational 
methods. For inclusion in the review, studies had to include an 
explicit definition of what was considered an ADR and/or an 
explicit assessment of causality, as well as a clear description 
of the method used for ADR identification, and had to explore 
factors associated with an increased risk of an ADR.
Exclusion criteria
Studies lacking a precise ADR definition or those without 
explicit causality assessment criteria, those that focused on 
ADRs secondary to a specific medication or specific ADR, 
and studies that looked at ADR-related hospital readmissions 
were excluded from the review. Studies that did not report 
ADR prevalence data or allow calculation of prevalence 
were also excluded.
Data extraction, synthesis, and analysis
Data were extracted, including ADR definition, identifica-
tion method, risk factors, and prevalence, using a custom-
designed data extraction form. Where the prevalence was 
not directly reported in the original publication, it was 
calculated as the number of patients identified with an ADR 
out of all included patients. Extracted data were entered 
into Microsoft Excel™ for descriptive data analysis. Over-
all median ADR prevalence as well as median prevalence 
of ADRs, leading to hospitalization and those occurring 
during inpatient stay, were calculated along with the 
 corresponding 95% confidence intervals (CIs). The quality 
of included studies was determined using the Strengthening 
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the  Reporting of Observational Studies in Epidemiology 
(STROBE) criteria for observational studies.13 The protocol 
for this systematic review was registered on the International 
Prospective Register of Systematic Reviews (PROSPERO) 
international prospective register of systematic reviews 
(CRD42013006827).14
Results
Fourteen hospital-based observational studies exploring 
ADRs in the elderly in acute care settings were identified and 
eligible for inclusion in this review (Figure 1). The size and 
design of the studies varied from large retrospective obser-
vational administrative data cohorts to smaller prospective 
studies in the clinical setting. The included studies ranged 
in size from a small prospective study of 80 patients pre-
senting to Emergency in Belgium15 to a large population-
based cohort of 64,446 Canadian hospital admissions.16 
The majority of studies were conducted in Europe (n=10), 
with two studies from Asia and two from North America. 
Characteristics and a summary of the included studies are 
presented in Table 1.
Prevalence of ADRs in the elderly
The mean prevalence of ADRs in the elderly in the stud-
ies included in this review was 11.0% (95% CI: 5.1–16.8). 
The median prevalence of ADRs leading to hospitalization 
Figure 1 Search strategy and identification of included studies.
Abbreviation: ADR, adverse drug reaction.
3,713 articles retrieved by
all searches
1,147 articles removed (duplicates)
2,566 articles screened for
relevance
Full text for 438 potentially
relevant articles revised
40 ADR studies in elderly
patients in hospital setting
14 studies included in this
review
2,128 unrelated articles excluded on
title/abstract (irrelevent studies)
398 excluded on full text:
– ADRs was not main aim (157)
– Nonacute care setting (99)
– ADR of specific condition or treatment (35)
– Studies in nonelderly populations (22)
– Non-English language (12)
– Systematic reveiws, review articles, journals,
   editorials, or abstracts only (73)
26 excluded studies:
– Study year (<2003) (9)
– Definition of elderly (age <65 years) (10)
– Study design/methods (7)




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Adverse drug reactions in the elderly
was 10.0% (95% CI: 7.2%–12.8%), while the prevalence of 
ADRs occurring during hospitalization was 11.5% (95% CI: 
0%–27.7%). There was wide variation in the overall ADR 
prevalence reported in the studies in this review, from a 
prevalence of 5.8% in 1,756 older Italian patients17 to 46.3% 
in a smaller Belgian study.15 Prospective studies were asso-
ciated with higher prevalence rates than were retrospective 
studies (Table 1). Larger studies generally tended to report 
higher prevalence rates, with the exception of the French 
study by Laroche et al.18 
Defining and identifying ADRs
The use of a predefined definition of ADRs or explicit assess-
ment of causality was an inclusion criterion for this analysis. 
In general, there was consensus regarding the definitions of 
ADRs. The majority of the studies (n=8) used either the WHO 
definition1 or that proposed by Edwards and Aronson:
An appreciably harmful or unpleasant reaction, resulting 
from an intervention related to the use of a medicinal prod-
uct, which predicts hazard from future administration and 
warrants prevention or specific treatment, or alteration of 
the dosage regimen or withdrawal of the product.19 
Only two studies used custom predefined definitions.20,21 
Half (n=7) of the studies included in this review described 
an explicit causality assessment. The most commonly 
used criteria were the Naranjo et al criteria,21 used by 
three studies. Two studies used the French method of 
causality assessment,22 one used the Hallas et al criteria23 
and one the WHO-Uppsala Monitoring Committee crite-
ria25 (Table 1). There did not appear to be a relationship 
between the use of explicit casualty criteria and the ADR 
prevalence reported.
A number of methods were used to identify ADRs in the 
included studies. Most studies (n=8) used a systematic medi-
cal review where a dedicated study team identified potential 
ADRs. A number of studies (n=6) relied upon physician 
reporting, where ADRs were identified as part of usual 
care.16,17,20–27 Four prospective studies relied on identifica-
tion of potential ADRs by physician reporting,17,21,26,28 while 
the remaining two studies were retrospective cohort studies 
using administrative datasets and identified potential ADRs 
retrospectively from the medical record.16,20 The majority 
of studies (n=10) outlined separate processes in addition to 
usual care for the identification of potential ADRs.15,17,18,27–33 
These usually involved identification of a potential ADR by a 
member or members of the research team and then systematic 
medical review of the potential ADR via expert panel review. 
Only one study provided explicit detail regarding the criteria 
used to screen patients for potential ADRs.33 
Medications associated with ADRs
There was considerable variation in the medications involved 
in the ADRs reported in the studies. Many studies found 
cardiovascular medications to be commonly associated 
with ADRs in the elderly, in particular antihypertensive 
and antithrombotic medications.16–18,26–28 Other implicated 
medications included antibiotics,26,27 nonsteroidal anti-
inflammatories,17,27 and antidiabetic agents.29
ADR-associated risk factors in the elderly
A number of risk factors associated with ADR in the elderly 
in acute care were identified in this review. These have been 
categorized as patient factors, disease factors, medication 
factors, or other factors (Table 2). 
While all studies were conducted on populations aged 
65 years or older, two studies found increasing age to be 
an independent ADR risk factor.16,32 Female sex was also 
consistently identified as a risk factor in the majority of 
studies.15,16,28,30 
Increasing medical complexity, both in terms of 
increasing comorbid burden16,25,29 and increased number of 































Other factors History of falls26
Limitations in activities of daily living26
Abbreviation: ADR, adverse drug reaction. 





medications,15,18,20,25–27,30,32 were both reported to be associated 
with an increased ADR risk, in a number of studies.
Discussion
The findings of this systematic review indicate that ADRs 
constitute a significant health care issue for the elderly in the 
acute care setting, suggesting that more than one in every 
ten older patients in the hospital setting experience an ADR, 
either leading to or during their hospital admission. 
Previous work has estimated that up to 17% of all adult 
patients admitted to hospital experience an ADR either 
leading to or during their hospital admission.34 A large 
meta-analysis suggested that the elderly had a four times 
higher risk of an ADR than did the general adult population; 
however, this meta-analysis was not focused specifically 
on the elderly and analyzed the over-65 age group as a 
subgroup analysis.34 There was wide variability in the ADR 
prevalence rates reported in this review, ranging from just 
over 5% to almost 50% of elderly patients. Heterogeneity in 
how ADRs are defined and identified are likely to account 
for much of this variability. In our review, higher prevalence 
rates tended to be found in larger studies and those using a 
prospective design. 
The majority of studies in the analyses used either the 
WHO definition1 of an ADR or that proposed by Edwards 
and Aronson.19 While these definitions have fundamental 
similarities in terms of harm associated with use of phar-
macological products, distinct differences exist in terms 
of what is considered an ADR under each definition, espe-
cially with respect to minor ADRs. The WHO definition 
does not specify a level of harm in the initial identification 
of a potential ADR and may capture more minor ADRs, 
which while having a significant impact on quality of life, 
do not lead to serious outcomes such as death, disability, 
or hospitalization. Another difference between the two 
definitions is the focus in the WHO description on a “drug” 
as the causative agent, rather than a “medicinal product”, 
as specified in the Edwards and Aronson definition. The 
broader Edwards and Aaronson definition may be inter-
preted to encourage the inclusion of reactions associated 
with complementary and herbal preparations and may thus 
affect the ADR prevalence rates reported. In general, in 
the studies included in this review, those using the WHO 
definition reported a narrower prevalence range than did 
those using the Edwards and Aaronson definition. How-
ever, ADR definition is only one factor that will contribute 
to differences reported between the studies with respect 
to prevalence. 
Differences in the methods used to detect ADRs may be 
another factor contributing to the wide range of prevalence 
rates reported. A number of studies relied on the identification 
of ADRs during routine care; however, underidentification35,36 
and underreporting37–39 of ADRs during routine care in the 
acute care setting has been well documented in the litera-
ture, and such methods are likely to underestimate the true 
prevalence of ADRs. This may have been the case in the 
Sikdar et al study, which relied on identification of ADRs 
during routine clinical care and then further relied on these 
episodes being accurately coded in the administrative dataset 
from which they were identified.16 While this study had the 
largest sample size in the review (n=64,446), the reliance on 
ADR identification during routine clinical care would have 
excluded undiagnosed ADRs and may have contributed 
toward one of the lowest reported prevalence rates among 
the included studies. It is important to note that retrospec-
tive studies rely on routine detection of ADRs as captured 
in medical records and case notes and may underrepresent 
the true ADR prevalence. Two other studies that also relied 
on routine detection of ADRs also reported relatively low 
prevalence rates,25,26 further supporting concerns regarding 
the possible underdetection of ADRs during routine care. 
While there was variation in the medications associated 
with ADRs in the elderly across the 14 studies included in 
this review, there were medications common to a number 
of studies, which may raise concerns regarding their safe 
use in the elderly. Cardiovascular medications were associ-
ated with ADRs in the elderly in a number of the studies 
in this review.16–18,26–28 Specific cardiovascular medica-
tions identified included antihypertensives, diuretics, and 
angiotensin-converting enzyme inhibitors, all of which 
have been associated with a number of issues, such as 
falls and electrolyte disturbances, in the elderly;40,41 further 
investigation may be required to fully understand their role 
in ADR risk. 
Despite the heterogeneity among the studies, there was 
considerable consistency in the risk factors associated with 
ADRs in elderly inpatients. Female sex was consistently 
identified as a risk factor; however, it was unclear whether 
this related to an increased ADR risk or an increased use of 
medications.15,16,28,30 Advanced age was found a risk factor by 
two of the studies in this review studies.16 Increased age was 
not only associated with increased frailty and physiological 
changes resulting in changed pharmacokinetics and dynam-
ics, but also, with increased medical complexity, disease 
burden and medication use. Both increased disease burden 
and medication number were identified as independent risk 
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factors for ADRs in the elderly; however, teasing out the 
complex relationship between aging, disease burden, medica-
tion use, and the risk of an ADR remains problematic. While 
disease burden was identified as a risk factor in a number of 
studies,16,25,29 there was great diversity regarding the role of 
specific conditions, making it difficult to fully understand 
the contribution of specific conditions to the risk of ADRs 
in the elderly. 
A main strength of this study was the strict inclusion 
criteria applied regarding ADR definitions and identifica-
tion. The review was limited to studies that included explicit 
criteria for both what was considered an ADR and how the 
ADRs were assessed in terms of causality. In addition, all 
studies required clear description of the method applied in 
the identification of the ADRs. The review was limited to 
observational studies in the acute care setting that focused 
specifically on ADRs in patients aged 65 years and older, in 
an attempt to minimize the heterogeneity among included 
studies. However, despite the strict inclusion criteria, con-
siderable heterogeneity was found among the 14 studies 
included in this review. The quality of included studies varied 
extensively. While most of the included studies fulfilled more 
than 50% of the STROBE criteria and could be considered 
to have moderate quality,42 no study met these criteria com-
pletely. Of particular note, only three studies reported a priori 
sample size calculations. Sample size calculations for cross-
sectional studies are based upon the expected prevalence of 
the parameter under investigation, and small sample sizes 
may not provide adequate precision. In this review, studies 
with smaller sample sizes tended to have higher prevalence 
estimates. This heterogeneity limited the ability to pool data 
and provide summary estimates for ADR prevalence across 
the total review population.
Conclusion
ADRs constitute a significant health issue for the elderly in 
the acute care setting. This review identified that at a conser-
vative estimate, one in ten elderly patients will experience 
an ADR leading to or during their hospital stay and that 
older patients with an increased disease burden and using 
a higher number of medications are at increased risk of an 
ADR leading to or during their hospital stay. Differences 
in what is considered an ADR and in the identification of 
potential ADRs lead to considerable heterogeneity between 
studies examining ADRs in the elderly. Future research 
focused on identifying and minimizing the risks of ADRs 
in the elderly is needed, to aid clinicians in the optimal use 
of pharmacotherapy in older patients. 
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